The ASCO abstract presentation is a near-term catalyst likely to drive trading activity. Traders should monitor for data disclosures on efficacy and safety from the first-in-human study, which could revalue the pipeline despite the company's small market cap.
Price Chart
Executive Summary
Aprea Therapeutics announced that early results from the first-in-human Phase 1 trial of its WEE1 inhibitor APR-1051 will be presented at the 2026 ASCO Annual Meeting. This marks a clinical milestone for the company's lead oncology program in biomarker-defined solid tumors.
Key Facts
- APRE announced acceptance of an abstract for APR-1051 Phase 1 trial results at ASCO 2026
- Presentation scheduled for May 30, 2026, during Developmental Therapeutics session
- APR-1051 is an oral WEE1 inhibitor in development for advanced solid tumors
- Trial identifier: NCT06260514
- Company has multiple clinical-stage oncology programs, including ATRN-119
Financial Impact
Non-financial clinical milestone with potential to increase investor sentiment and valuation interest
Risk Factors
- Early-phase data may show limited efficacy or safety concerns
- Low market cap and limited liquidity increase volatility risk
- Forward-looking statements subject to clinical development risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278152 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 8w ago | 8-K | $0.8386 | awaiting T+60 | — | $0.5180 (−38.23%) |
Aug 12, 2026 10w ago | 8-K | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
Aug 12, 2026 10w ago | Press Release | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
May 13, 2026 23w ago | 8-K | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
May 13, 2026 23w ago | Press Release | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
Apr 30, 2026 25w ago | DEFA14A | $0.8000 $0.6247 | ▲ +21.91% | ▲ +25.02% | $0.5180 (+35.25%) |
Apr 22, 2026 26w ago | S-3 | $0.8840 $0.6690 | ▲ +24.32% | ▲ +29.34% | $0.5180 (+41.40%) |
Apr 21, 2026 26w ago | Press Release | $0.9070 $0.6900 | ▼ −23.93% | ▼ −30.82% | $0.5180 (−42.89%) |
Mar 31, 2026 29w ago | Insider Cluster | $0.7630 $0.7900 | ▲ +3.54% | ▼ −8.84% | $0.5180 (−32.11%) |
Mar 20, 2026 31w ago | EFFECT | $0.7620 $0.6990 | ▼ −8.27% | ▼ −22.69% | $0.5180 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers